13.12
price down icon7.15%   -1.01
pre-market  Vorhandelsmarkt:  13.18   0.06   +0.46%
loading
Schlusskurs vom Vortag:
$14.13
Offen:
$14.15
24-Stunden-Volumen:
4.45M
Relative Volume:
2.12
Marktkapitalisierung:
$1.34B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-2.4029
EPS:
-5.46
Netto-Cashflow:
$-382.65M
1W Leistung:
-18.56%
1M Leistung:
-37.76%
6M Leistung:
-49.32%
1J Leistung:
-56.67%
1-Tages-Spanne:
Value
$12.82
$14.27
1-Wochen-Bereich:
Value
$12.82
$16.28
52-Wochen-Spanne:
Value
$12.82
$34.87

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Firmenname
Intellia Therapeutics Inc
Name
Telefon
857-285-6200
Name
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
598
Name
Twitter
@intelliatweets
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
NTLA's Discussions on Twitter

Vergleichen Sie NTLA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
NTLA 13.12 1.34B 45.97M -508.80M -382.65M -5.46
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-04-13 Eingeleitet Canaccord Genuity Buy
2023-03-21 Eingeleitet Bernstein Outperform
2023-03-14 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2023-01-24 Hochstufung Citigroup Sell → Neutral
2023-01-19 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 Eingeleitet Morgan Stanley Overweight
2022-09-21 Eingeleitet JP Morgan Overweight
2022-09-01 Eingeleitet Citigroup Sell
2022-06-17 Eingeleitet BMO Capital Markets Market Perform
2022-06-16 Eingeleitet BofA Securities Buy
2022-04-28 Eingeleitet Credit Suisse Outperform
2022-02-18 Eingeleitet William Blair Outperform
2022-02-07 Hochstufung Oppenheimer Perform → Outperform
2022-01-31 Eingeleitet Cowen Outperform
2022-01-07 Eingeleitet Piper Sandler Overweight
2021-10-05 Eingeleitet Guggenheim Buy
2021-09-24 Eingeleitet Stifel Buy
2021-06-28 Bestätigt H.C. Wainwright Buy
2021-06-11 Eingeleitet H.C. Wainwright Buy
2021-05-07 Hochstufung ROTH Capital Neutral → Buy
2021-05-04 Eingeleitet RBC Capital Mkts Outperform
2021-03-04 Eingeleitet JMP Securities Mkt Outperform
2020-12-22 Herabstufung Robert W. Baird Outperform → Neutral
2020-10-27 Eingeleitet Truist Buy
2020-10-14 Eingeleitet Wells Fargo Overweight
2020-09-18 Eingeleitet Goldman Buy
2020-02-28 Hochstufung Oppenheimer Perform → Outperform
2020-02-14 Herabstufung Wedbush Outperform → Neutral
2019-11-01 Hochstufung Raymond James Mkt Perform → Outperform
2019-07-09 Eingeleitet Robert W. Baird Outperform
2019-06-10 Eingeleitet ROTH Capital Neutral
2019-05-03 Hochstufung Wedbush Neutral → Outperform
2019-04-12 Eingeleitet Evercore ISI Outperform
2018-11-02 Herabstufung Wedbush Outperform → Neutral
2018-10-29 Eingeleitet Credit Suisse Neutral
2018-09-21 Eingeleitet Raymond James Mkt Perform
2018-05-15 Hochstufung Chardan Capital Markets Neutral → Buy
2018-03-08 Eingeleitet JMP Securities Mkt Outperform
2017-11-01 Bestätigt Jefferies Buy
2017-06-22 Fortgesetzt Jefferies Buy
2017-03-28 Eingeleitet Chardan Capital Markets Buy
2016-08-05 Hochstufung Jefferies Hold → Buy
Alle ansehen

Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten

pulisher
07:34 AM

Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat

07:34 AM
pulisher
Nov 20, 2024

Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

CF Foundation invests $15M in Recode Therapeutics to boost CF gene editing - Cystic Fibrosis News Today

Nov 19, 2024
pulisher
Nov 19, 2024

Intellia Therapeutics Announces Promising CRISPR Therapy Results - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo - Yahoo Finance

Nov 19, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) - Seeking Alpha

Nov 18, 2024
pulisher
Nov 18, 2024

Wells Fargo & Company Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00 - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest - BioPharma Dive

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia stock touches 52-week low at $13.94 amid biotech slump - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Intellia’s gene editing therapy shows early potential in rare heart condition - Clinical Trials Arena

Nov 18, 2024
pulisher
Nov 18, 2024

CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy - Yahoo Finance

Nov 18, 2024
pulisher
Nov 18, 2024

The Best Biotech Stocks to Buy - Morningstar

Nov 18, 2024
pulisher
Nov 16, 2024

Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's Why - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire

Nov 16, 2024
pulisher
Nov 16, 2024

Intellia's CRISPR Therapy Shows 90%+ Disease Protein Reduction in Key Clinical Trial | NTLA Stock News - StockTitan

Nov 16, 2024
pulisher
Nov 16, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Gene Editing Tools Market Size, Growth Opportunities, - openPR

Nov 15, 2024
pulisher
Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Has $64.72 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Intellia Therapeutics (FRA:38I) Operating Income : €-492.77 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

When (NTLA) Moves Investors should Listen - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 12, 2024

Intellia Therapeutics' SWOT analysis: gene editing stock's progress and potential - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024
pulisher
Nov 11, 2024

3 Fast-Growing Stocks Analysts See Doubling in Price - sharewise

Nov 11, 2024
pulisher
Nov 11, 2024

Oppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus (NASDAQ:NTLA) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 11, 2024

Brookline Capital Management Forecasts NTLA FY2027 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript - MSN

Nov 10, 2024
pulisher
Nov 09, 2024

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus - MSN

Nov 09, 2024
pulisher
Nov 09, 2024

Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Earnings: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors - Morningstar

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 by Analysts at Barclays - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... - Yahoo Finance Australia

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Buys 659,651 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics Reports Q3 2024 Financial Progress - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39) - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Intellia (NTLA) Advances Phase 3 Trials Despite $135.7M Loss; $944.7M Cash Runway to 2026 | NTLA Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Harbor Capital Advisors Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024

Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Clark Eliana
EVP, Chief Technical Officer
Jul 01 '24
Sale
22.93
405
9,287
71,470
Verwiel Frank
Director
Jun 17 '24
Sale
25.00
1,505
37,625
17,948
BASTA JAMES
EVP, General Counsel
Mar 04 '24
Sale
32.99
2,297
75,778
81,571
Clark Eliana
EVP, Chief Technical Officer
Mar 04 '24
Sale
32.99
605
19,959
71,470
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Jan 08 '24
Sale
28.87
2,275
65,682
43,927
LEONARD JOHN M
President and CEO
Jan 03 '24
Sale
29.46
19,223
566,310
846,486
Lebwohl David
EVP, Chief Medical Officer
Jan 03 '24
Sale
29.46
5,843
172,135
54,372
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Jan 03 '24
Sale
29.46
5,532
162,973
46,202
Goddard Glenn
EVP, Chief Financial Officer
Jan 03 '24
Sale
29.46
5,365
158,053
40,585
Hicks Derek
EVP, Chief Business Officer
Jan 03 '24
Sale
29.46
3,877
114,216
36,987
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Kapitalisierung:     |  Volumen (24h):